Journal of Clinical Immunology

, Volume 39, Issue 1, pp 19–22 | Cite as

Successful Treatment with SCIG of a Child with Refractory Chronic ITP

  • Anna KarastanevaEmail author
  • Daniela S. KlobassaEmail author
  • Milen Minkov
  • Martin Benesch
  • Markus G. Seidel
Letter to Editor

To the Editor

Immune thrombocytopenia (ITP) is mediated by autoantibodies and characterized by destruction and impaired production of platelets. Primary ITP is a rare, idiopathic autoimmune disorder with an incidence of 3–5 per 100,000 children per year [1], whereas secondary ITP is related to coexisting conditions such as immunodeficiency, rheumatological disorders, infectious diseases, and others [2]. Persistence over 12 months is referred to as chronic ITP (cITP) and bears a significant disease burden due to hemorrhagic, thrombotic, or therapy-associated complications. Besides corticosteroids, intravenous immunoglobulins (IVIG) are a standard first-line therapy for ITP. It is assumed that IVIG positively affects the platelet count and the bleeding diathesis by immunomodulation and stimulation of thrombopoiesis [3].

In patients with humoral immune deficiencies requiring IgG substitution, the subcutaneous application route of Ig (SCIG) has demonstrated a range of benefits compared to...



The authors thank the patient and her family for the approval to publish her clinical history and laboratory data. MGS is in part funded by the Styrian Children’s Cancer foundation (Steirische Kinderkrebshilfe).

Authors’ Contribution

AK and MGS designed the study. AK, DK, HL, MB, and MGS cared for the patient and collected data. AK and DK analyzed the data. MM gave relevant advice in patient care and the discussion of the data. DK drafted the manuscript and the figures.

Compliance with Ethical Standards

Ethics Statement

Written informed consent was obtained from the participant’s next of kin for the publication of this patient report, which was conducted according to the Declaration of Helsinki.

Conflict of Interest

The authors declared that they have no conflict of interest.


  1. 1.
    Kuhne T. Diagnosis and management of immune thrombocytopenia in childhood. Hamostaseologie. 2017;37(1):36–44.CrossRefGoogle Scholar
  2. 2.
    Seidel MG. Autoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment. Blood. 2014;124(15):2337–44.CrossRefGoogle Scholar
  3. 3.
    Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol. 2011;127(2):315–23 quiz 24-5.CrossRefGoogle Scholar
  4. 4.
    Iuliano F, Iuliano E, Luci M, Perricelli A, Pomillo A, Abruzzese E. Subcutaneous immunoglobulin (SCIG) in responders to intravenous therapy with chronic immune thrombocytopenia (ITP). Blood. 2014;124(21):5012.Google Scholar
  5. 5.
    Pedini V, Savore I, Danieli MG. Facilitated subcutaneous immunoglobulin (fSCIg) in autoimmune cytopenias associated with common variable immunodeficiency. Isr Med Assoc J. 2017;19(7):420–3.Google Scholar
  6. 6.
    Scheuerlein P, Pietsch L, Camacho-Ordonez N, Reiser V, Patel S, Burns SO, et al. Is it safe to switch from intravenous immunoglobulin to subcutaneous immunoglobulin in patients with common variable immunodeficiency and autoimmune thrombocytopenia? Front Immunol. 2018;9:1656.CrossRefGoogle Scholar
  7. 7.
    Chapdelaine H, Decaluwe H, Levasseur MC, De Deist F, Haddad E. Experience with subcutaneous immunoglobulin therapy in two pediatric cases of immune thrombocytopenia purpura. Allergy, Asthma Clin Immunol. 2012;8(Suppl 1):A23.CrossRefGoogle Scholar
  8. 8.
    Cuker A, Neunert CE. How I treat refractory immune thrombocytopenia. Blood. 2016;128(12):1547–54.CrossRefGoogle Scholar
  9. 9.
    DiMaggio D, Anderson A, Bussel JB. Cytomegalovirus can make immune thrombocytopenic purpura refractory. Br J Haematol. 2009;146(1):104–12.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Research Unit for Pediatric Hematology and ImmunologyMedical University GrazGrazAustria
  2. 2.Divison of Pediatric Hematology-Oncology, Department of Pediatrics and Adolescent MedicineMedical University GrazGrazAustria
  3. 3.Department of Pediatrics and Adolescent MedicineKrankenhaus RudolfstiftungViennaAustria

Personalised recommendations